Medicines Used to Stop Bleeding (Hemostatic Agents)

1. Antifibrinolytics - Aminocaproic Acid & Tranexamic Acid

• Mechanism: Both drugs are synthetic agents that inhibit plasminogen activation, thereby blocking fibrinolysis (the breakdown of blood clots). Tranexamic acid is 10 times more potent than aminocaproic acid.
• Route: Both are orally active and excreted by the kidneys (dose reduction needed in renal impairment).
• Uses:
  • Surgical bleeding, trauma hemorrhage (e.g., CRASH-2 trial for trauma)
  • Heavy menstrual bleeding (tranexamic acid is FDA-approved for this)
  • Hemophilia (minor mucosal bleeding, as adjunct)
  • Epistaxis (topical tranexamic acid)
• Key side effect: Risk of intravascular thrombosis (clot formation in vessels).

2. Vitamin K1 (Phytonadione)

• Mechanism: Vitamin K1 is required for the liver to synthesize clotting factors II, VII, IX, and X. When warfarin (a blood thinner) causes bleeding, giving vitamin K1 replenishes active vitamin K, reversing warfarin's effect.
• Routes: Oral, subcutaneous, or IV (IV should be given slowly to avoid anaphylaxis).
• Onset: Slow - takes about 24 hours to lower INR (time needed to synthesize new clotting factors).
• If immediate hemostasis is needed: Fresh Frozen Plasma (FFP) should be given instead of, or alongside, vitamin K1.
• Monitoring: PT/INR

3. Protamine Sulfate

• Use: Reverses heparin-induced bleeding.
• Mechanism: Protamine is a protein (derived from fish sperm) that is strongly positively charged. It binds to negatively charged heparin and forms an inactive complex, neutralizing the anticoagulant effect.
• Adverse effects: Hypersensitivity, flushing, nausea/vomiting, breathlessness, bradycardia, hypotension - especially if injected rapidly.

4. Idarucizumab (Praxbind)

• Use: Reverses bleeding caused by dabigatran (a direct thrombin inhibitor).
• Mechanism: A monoclonal antibody fragment that binds dabigatran and neutralizes its anticoagulation effect.
• Route: IV, used in emergency settings.
• Key risk: Thrombosis (since it reverses anticoagulation).

5. Andexanet Alfa (Factor Xa)

• Use: Reverses life-threatening bleeding caused by apixaban or rivaroxaban (Factor Xa inhibitors).
• Mechanism: A recombinant modified human protein that binds and sequesters apixaban/rivaroxaban, preventing them from inhibiting Factor Xa.
• Key risks: Arterial/venous thromboembolism, MI, stroke, cardiac arrest.
• Note: NOT approved for edoxaban reversal.

6. Desmopressin (DDAVP)

• Use: Mild hemophilia A, von Willebrand disease (Type 1), platelet dysfunction.
• Mechanism: A synthetic analog of vasopressin (ADH) that acts on V2 receptors in endothelial cells, causing release of von Willebrand Factor (vWF) and Factor VIII from storage.
• Route: IV, subcutaneous, or nasal spray.
• Key point: Only useful in mild hemophilia A (not severe, where factor levels are too low).

7. Concentrated Clotting Factor Products

8. Topical Hemostatic Agents

• Topical thrombin - activates fibrin clot formation locally
• Fibrin glue/sealant - mimics the final step of coagulation
• Topical tranexamic acid - applied directly to bleeding wounds
• Gelatin/collagen sponges (e.g., Gelfoam) - physical scaffolds for clot formation

Quick Reference: Match Drug to Cause of Bleeding

Important note: Always identify the cause of bleeding before choosing a drug. Using the wrong agent can either be ineffective or cause dangerous thrombosis (clotting in blood vessels). For serious or unexplained bleeding, seek immediate medical attention.